Hexarelin
Phase I TrialsAlso known as: Examorelin
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
Hexarelin is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate GH release and its potential cardioprotective effects in animal models and early human studies.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Muscle Recovery & Repair
- Growth Hormone Regulation
- Cardiovascular Health
Acts as a GHSR-1a agonist to stimulate GH release. Additionally, research has identified GHSR-independent cardioprotective pathways, with Hexarelin studied in the context of cardiac ischemia models.
Phase I safety data available. More potent cortisol and prolactin-stimulating effects compared to Ipamorelin. Not FDA-approved.
Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.
- Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction
McDonald H et al. (2018). Physiological Reports.
- Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion
McDonald H et al. (2020). Peptides.
Want to learn more?
Ask Research Chat about HexarelinHalf-Life
~3 hours
Administration
subcutaneous injection, intravenous (in research)
Legal Status (US)
Research chemical in the US. Not FDA-approved.
160 indexed research passages
Related Peptides
GHRP-2 (pralmorelin) is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate pulsatile GH release through the ghrelin receptor. It has been investigated in clinical studies and is sometimes used diagnostically for growth hormone deficiency assessment in some countries.
IGF-1 (insulin-like growth factor 1) is an endogenous polypeptide hormone critical for growth, development, and metabolic homeostasis. It is produced primarily in the liver in response to GH signaling and acts through IGF-1 receptors on virtually all tissues. Recombinant IGF-1 (mecasermin) is FDA-approved for children with severe primary IGF-1 deficiency.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification to improve stability. It is FDA-approved for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients receiving antiretroviral therapy, and has been studied for cognitive function in aging.
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in multiple countries including China, Japan, and the EU for the management of anemia associated with chronic kidney disease. It stimulates endogenous erythropoietin production by stabilizing HIF-alpha proteins.